{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017836","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.687824+00:00","generated_at":"2026-06-21T20:35:29.162747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mustang Bio Q3 2022 net loss $19.0M ($0.18/sh); cash $92.4M; MB-106 trial advances","bullets":["Cash and equivalents $92.4M at Sep 30, 2022, down $16.0M from June 30, $110.6M at Dec 31, 2021.","Net loss attributable to common stockholders $19.0M ($0.18/sh) vs $17.0M ($0.19/sh) in Q3 2021.","First patient treated in Mustang-sponsored multicenter Phase 1/2 trial for MB-106 (CD20 CAR T) in B-NHL and CLL.","Fred Hutch trial: 96% ORR, 75% CR in 28 patients; 12 patients CR >12 months; no Grade ≥3 CRS or ICANS.","MB-106 granted FDA Orphan Drug Designation for Waldenstrom macroglobulinemia; early Phase 1 results expected Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017836","json":"https://secwatch.observer/filing/0001558370-22-017836.json","markdown":"https://secwatch.observer/filing/0001558370-22-017836.md","text":"https://secwatch.observer/filing/0001558370-22-017836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/0001558370-22-017836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/tmb-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:35:29.162747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b761f683b20e6fb91ad7bf88f698ef12bcd9f9c5","claim":"MUSTANG BIO, INC. reported the third quarter ended September 30, 2022 results: net income $19.0 million, or $0.18 per share, EPS $0.18 per share.","evidence_excerpt":"Net loss attributable to common stockholders was $19.0 million, or $0.18 per share, for the third quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837022017836/0001558370-22-017836-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$19.0 million, or $0.18 per share"},{"label":"EPS","value":"$0.18 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}